Two market reports point to rapid expansion in obesity-treatment medicines through 2035, while covering different scopes: SNS Insider forecasts the global Wegovy market will rise from USD 2.95 billion in 2025 to USD 29.41 billion in 2035 at a 25.96% CAGR from 2026 to 2035, and ResearchAndMarkets.com forecasts the broader anti-obesity drugs market from USD 45.1 billion in 2026 to USD 106.5 billion in 2035 at approximately 10.0% annual growth. Both reports cite rising obesity prevalence, GLP-1 receptor agonist adoption, cardiometabolic benefits, broader reimbursement and treatment access as drivers. North America currently leads both markets, while Asia-Pacific is expected to grow fastest. Oral candidates, manufacturing investment and expanding competition could broaden access, although research costs, regulatory requirements, supply constraints, adverse events and long-term safety remain challenges.